Syndax’s Early Commercial Momentum Signals Big 2026 Growth Ahead

Syndax Pharmaceuticals (SNDX) appears to be building serious momentum — its early commercial rollout is pointing to a potentially explosive 2026. In Q3 2025, Syndax delivered strong growth fueled by rising sales of Revuforj and Niktimvo. Revuforj prescriptions jumped about 25%, while management remains confident that existing cash reserves will support operations until profitability. Analysts are forecasting 2026 revenue somewhere between US$245 million and US$512 million, depending on how aggressive the ramp-up is. Even though Syndax currently reports a GAAP loss (–US$0.70 per share), that’s actually slightly better than expected. Revenue reached roughly US$45.9 million in Q3 — up 267% year-over-year — though still modestly below estimates. The optimism isn’t unfounded. Syndax’s expanding commercial footprint, combined with Revuforj’s potential label extensions and the early success of Niktimvo, give it a first‑mover advantage in critical therapeutic segments. Unless reimbursement or competitive pressures derail things, the company looks positioned for a strong 2026. #Syndax #Biotech #Revuforj #2026Growth #SlimScan #GrowthStocks #CANSLIM